To receive daily emails from Breaking Christian News to your inbox CLICK HERE

Holly Auer : Feb 1, 2012  Perelman School of Medicine - University of Pennsylvania

Majority of patients treated develop strong, lasting immune responses.

(Philadelphia, PA)—Researchers at the Perelman School of Medicine and the Abramson Cancer Center at the University of Pennsylvania report that a short course of vaccination with an anti-HER2 dendritic cell vaccine made partly from the patient's own cells triggers a complete tumor eradication in nearly 20 percent of women with ductal carcinoma in situ (DCIS), an early breast cancer. More than 85 percent of patients treated appear to have a sustained immune response after vaccination, which may reduce their risk of developing a more invasive cancer in the future. The results of the study were published online this month of Cancer and in the January issue of the Journal of Immunotherapy.

The researchers say the results provide new evidence that therapeutic breast cancer vaccines may be most effective for early, localized disease, and when the treatment attacks a protein critical to cancer cell survival.

"I think these data more than prove that vaccination works in situations where the target is right," says the study's leader, Brian Czerniecki, MD, PhD, surgical director of the Rena Rowan Breast Center and Surgical Director of the Immunotherapy Program for the Abramson Cancer Center. "Previous vaccines targeted tissue antigens that were expressed on the cancer cells, but were not necessary for tumor survival. So a vaccine response would cause the tumor to just stop expressing the antigen and the tumor would be fine. Here we're going after HER2/neu, which is critical for survival of early breast cancers. If we knock it out with the immune response, we cripple the tumor cells." (Photo: texasoncology.com)

The new approach has several critical advantages, compared to testing a vaccine in patients with more advanced disease. First, the activated immune cells have fewer tumor cells to kill. Second, patients' immune systems are still responsive, unlike advanced cancer patients whose immune systems have been suppressed by their disease. Third, the investigators are able to see results quickly, by looking at serum and tumor biomarkers.

In fact, when the team compared pre-vaccination biopsy samples with post-vaccination surgical samples, they saw dramatic changes: Five patients had no disease visible at the time of surgery, indicating that their immune system had wiped out the tumor. Of the remaining 22 patients, HER2 expression was eliminated in half (11 patients), and reduced by 20 percent or more in another two. "We are continuing to see this pattern in our second, ongoing trial," Czerniecki says.

When the team looked at immune responses, they found that 85 percent of patients had HER2-reactive CD4 and CD8 T cells, suggesting that the patients developed a robust and relatively complete immune response after vaccination. Importantly, some patients maintained their immune responses as long as 52 months, which means that they continue to have some protection from recurrence of HER2-positive disease—a key insurance policy for patients, since doctors currently are unable to accurately predict which women are likely to develop invasive breast cancer following a DCIS diagnosis.

The results of the study show the vaccine is safe and relatively easy for the women, with only low-grade side effects. The most common side effects were malaise (72 percent), injection site soreness (59 percent), chills or rigors (38 percent), fever (28 percent) and headaches (24 percent).

While the number of patients treated in the trial are relatively small, Czerniecki thinks they will have some idea whether the vaccination reduces the risk of disease recurrence within the next two years. In the meantime, the team continues enrolling patients in a larger study, is designing another study to test the approach in women with early invasive breast cancer, and also plans to test vaccination with additional antigens, including HER3 and HER1.

"I think if we target several of the HER2 family members, we'll drive the tumor to a place where it has nowhere to go," Czerniecki says. "Basically, we'll push it over a cliff because those pathways are critical for tumor survival."

Czerniecki notes that what the team is learning in DCIS is applicable to invasive breast cancer, and to other solid tumors that rely on the HER family of signaling proteins, including melanoma, lung, brain, and colon cancers.

To receive daily emails from Breaking Christian News to your inbox CLICK HERE

Ainsley Earhardt Celebrates America; Reveals Supernatural Experience That Strengthened Her Faith [Video]

Melania Trump Launches First-of-Its-Kind Foster Youth Accounts to Give Children Asset Ownership

Changing Tide: Record-low 38% of Americans Support 'Gender Transitions' - Gallup Poll

4 States Offering Pride Month Alternatives That Celebrate Family

PRO-LIFE WIN: Trump Admin Moves to Remedy Downfall of IVF

Karmelo Anthony Claims He's 'Penniless,' Can't Afford Lawyer for Appeal, Despite Pocketing $625,000, after Murder Conviction

Trump Says US Snuck 22 Oil Ships Past Iran in Covert Op, US Strikes Regime 2 Nights in a Row

Memphis Safe Task Force Surpasses 10,000 Arrests, Locates 154 Missing Children and Removes over 1,700 Firearms from City Streets

President Trump Signs $70 Billion Border Security, ICE Funding Bill that Includes Funding to Combat Child Trafficking

Report: Parents Remain Essential to Instilling Authentic Faith in Next Generation

Who Is Counseling Our Children?

Supreme Court Vacates Biden-Era Decision Outlawing Gas Stoves, Water Heaters

California Election: Our Republic in the Balance

Belfast Burns as Protests Turn Violent after Sudanese Migrant's Brutal Knife Attack Leaves Man Partially Blind

Texas Teen Gets 35 Years in Fatal Track Meet Stabbing

House Democrats Join Republicans to Defeat Lebanon War Powers Resolution, in Surprisingly Bipartisan Response

US Retaliates with Strikes on Iran after Regime Downs US Helicopter; Future of Ceasefire Uncertain

'I Still Have a Dream' – MLK Jr.'s Niece Rejects SPLC's Hate-Mongering in Powerhouse Testimony

Michigan Town Bans Church From Holding Worship Services: Lawsuit

Cleveland Clinic to Provide $2M for Detransition Care, Won't Perform Sex-Change Procedures for Minors

Steve Shultz, Managing Editor
Founder and Owner

Aimee Herd, Editor